Trial reportScientific reports2026
Effects of DRG pulsed radiofrequency parameters on the clinical outcome for battered sensory never syndrome: a prospective, triple-blind, randomized controlled trial.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
Battered Sensory Never Syndrome (BSNS) is a condition characterized by persistent, long-term mechanical compression of the sensory roots, dorsal root ganglia (DRG), and sensory fibers of the spinal nerve roots. This leads to symptoms such as hyperalgesia or allodynia, paresthesia, and radicular pain-like syndromes where pain worsens with weight-bearing or physical activity. High-voltage DRG pulsed radiofrequency (PRF) is effective for BSNS, but optimal treatment parameters for the best clinical efficacy remain undefined. This study aims to compare the clinical outcomes of various PRF temperatures and durations in patients with BSNS. Patients with BSNS were randomized to one of four high-voltage (80 V) PRF parameter groups: 42℃/3min, 42℃/12min, 55℃/3min, and 55℃/12min. The primary outcome measures included the Numerical Rating Scale (NRS) and the Oswestry Disability Index (ODI). The secondary outcome measures included the Hamilton Anxiety Scale (HAMA), the Hamilton Depression Scale (HAMD), the Pittsburgh Sleep Quality Index (PSQI) scores, the effective rate of pain relief, the proportion of patients with a ≥ 50% reduction in ODI score, and medication usage. These were evaluated before PRF and within 12 months after surgery. All patients included in our study had a mean age over 60, with the majority being female. Four patient groups showed significant reductions in NRS, ODI, HAMA, HAMD scores (P < 0.05) and decreased medication use within 12 months post-PRF, with no statistically significant differences between the groups (P > 0.05). The PSQI scores decreased significantly only in the 42 °C/3min group at 1 month,3 and 6 months (P < 0.05), also without intergroup significance (P > 0.05). The subgroup analysis by time and temperature revealed that NRS scores (P = 0.009), the number of patients with effective pain relief (P = 0.039) and ODI reduction ≥ 50% (P = 0.045) 1 month after PRF in the 55℃ group were significantly better than those in the 42℃ group, while no statistically significant difference was found between 3-min and 12-min durations (P > 0.05). High-voltage DRG PRF effectively treats BSNS patients within a treatment duration range of 3 to 12 min. Treatment at 55 °C offers superior pain relief and physical function improvement without neuropathic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.